Market Overview

Transgenomic to Hold Third Quarter Financial Results Conference Call on November 7, 2012

Share:
OMAHA, Neb.--(BUSINESS WIRE)--

Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:

   
What: Transgenomic, Inc. Third Quarter 2012 Financial Results and Business Update Conference Call
 
When: Wednesday, November 7, 2012 @ 5:00 p.m. Eastern
 
Where:

http://www.transgenomic.com/events.asp?id=6

 
How: Live over the Internet -- Simply log on to the web at the address above.
 
Contact: Investor Relations, 402-452-5416
 

To access the call via telephone, dial 866-952-1907 from the U.S. and Canada or 785-424-1826 for international participants and enter conference ID TRANS. A telephone replay will be available from 6:00 p.m. Eastern Time on November 7, 2012 through 11:59 p.m. Eastern Time on November 21, 2012 by dialing 800-723-0607 (domestic) or 402-220-2658 (international).

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is a global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.

For Transgenomic, Inc.
Investor Contact
Argot Partners
David Pitts, 212-600-1902
david@argotpartners.com
or
Company Contact
Transgenomic, Inc.
Investor Relations
402-452-5416
investorrelations@transgenomic.com









View Comments and Join the Discussion!